Comparison of evaluations for hormone receptors in breast carcinoma using two manual and three automated immunohistochemical assays

American Journal of Clinical Pathology

Volumn 127, Issue 3, 2007, Pages 356-365

  Arihiro, Koji ^a   Umemura, Shinobu ^b   Kurosumi, Masafumi ^c   Moriya, Takuya ^d   Oyama, Tetsunari ^e   Yamashita, Hiroko ^h   Umekita, Yoshihisa ^f   Komoike, Yoshifumi ⁱ   Shimizu, Chikako ^k   Fukushima, Hisaki ^j   Kajiwara, Hiroshi ^b   Akiyama, Futoshi ^g  

^a HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SAITAMA CANCER CENTER   (Japan)

^d TOHOKU UNIVERSITY HOSPITAL   (Japan)

^e DOKKYO MEDICAL UNIVERSITY   (Japan)

^f KAGOSHIMA UNIVERSITY   (Japan)

^g CANCER INSTITUTE HOSPITAL   (Japan)

^h NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

ⁱ OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^j KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k NATIONAL CANCER CENTER HOSPITAL   (Japan)

more..

Author keywords

Automated staining; Estrogen receptor; Hormone receptors; Immunohistochemistry; Progesterone receptor; Scoring system

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CARCINOMA; CANCER CELL; CLINICAL EVALUATION; CONTROLLED STUDY; HORMONE DETERMINATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABORATORY AUTOMATION; LABORATORY TEST; PRIORITY JOURNAL; SCORING SYSTEM; BREAST TUMOR; COMPARATIVE STUDY; EVALUATION; FEMALE; INSTRUMENTATION; METABOLISM; METHODOLOGY; PATHOLOGY; REPRODUCIBILITY;

BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REPRODUCIBILITY OF RESULTS;

EID: 34247884390     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/4D1A04NCDK96WFY7     Document Type: Article

References (45)

1. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005;16:1569-1583.
2. Fisher ER, Anderson S, Dean S, et al. Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma. Cancer. 2005;103:164-173.
3. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474-1481.
4. Mohsin SK, Weiss H, Havighurst T, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol. 2004;17:1545-1554.
5. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:966-978.
6. National Institutes of Health. Adjuvant therapy for breast cancer. NIH Consensus Statement. 2000;17:1-35.
7. Bast RC Jr, Ravdin P, Hayes DF, et al, and the American Society of Clinical Oncology Tumor Markers Expert Panel. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1865-1878.
8. Rhodes A, Jasani B, Barnes DM, et al. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol. 2000;53:125-130.
9. Werner M, Chott A, Fabiano A, et al. Effect of formalin tissue fixation and processing on immunohistochemistry. Am J Surg Pathol. 2000;24:1016-1019.
10. Olapade-Olaopa EO, Ogunbiyi JO, MacKay EH, et al. Further characterization of storage-related alterations in immunoreactivity of archival tissue sections and its implications for collaborative multicenter immunohistochemical studies. Appl Immunohistochem Mol Morphol. 2001;9:261-266.
11. Ferrero-Pous M, Trassard M, Le Doussal V, et al. Comparison of enzyme immunoassay and immunohistochemical measurements of estrogen and progesterone receptors in breast cancer patients. Appl Immunohistochem Mol Morphol. 2001;9:267-275.
12. Rudiger T, Hofler H, Kreipe HH, et al. Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 padiologists. Am J Surg Pathol. 2002;26:873-882.
13. Press M, Spaulding B, Groshen S, et al. Comparison of different antibodies for detection of progesterone receptor in breast cancer. Steroids. 2002;67:799-813.
14. Umemura S, Itoh H, Ohta M, et al. Immunohistochemical evaluation of hormone receptor for routine practice of breast cancer: highly sensitive procedures significantly contribute to the correlation with biochemical assays. Appl Immunohistochem Mol Morphol. 2003;11:62-72.
15. Goldstein NS, Ferkowicz M, Odish E, et al. Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol. 2003;120:86-92.
16. Ding SL, Sheu LF, Yu JC, et al. Expression of estrogen receptor-alpha and Ki67 in relation to pathological and molecular features in early-onset infiltrating ductal carcinoma. J Biomed Sci. 2004;11:911-919.
17. Vassallo J, Pinto GA, Alvarenga JM, et al. Comparison of immunoexpression of 2 antibodies for estrogen receptors (1D5 and 6F11) in breast carcinomas using different antigen retrieval and detection methods. Appl Immunohistochem Mol Morphol. 2004;12:177-182.
18. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, et al. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol. 2005;123:21-27.
19. Szeszel MK, Crisman CL, Crow L, et al. Quantifying estrogen and progesterone receptor expression in breast cancer by digital imaging. J Histochem Cytochem. 2005;53:753-762.
20. Grann VR, Troxel AB, Zojwalla NJ, et al. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer. 2005;103:2241-2251.
21. Mann GB, Fahey VD, Feleppa F, et al. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. J Clin Oncol. 2005;23:5148-5154.
22. Putti TC, El-Rehim DM, Rakha EA, et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol. 2005;18:26-35.
23. Collins LC, Botero ML, Schnitt SJ. Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases. Am J Clin Pathol. 2005;123:16-20.
24. Barnes NL, Boland GP, Davenport A, et al. Relationship between hormone receptor status and tumour size, grade and comedo necrosis in ductal carcinoma in situ. Br J Surg. 2005;92:429-434.
25. Layfield LJ, Saria EA, Conlon DH, et al. Estrogen and progesterone receptor status determined by the Ventana ES 320 automated immunohistochemical stainer and the CAS 200 image analyzer in 236 early-stage breast carcinomas: prognostic significance. J Surg Oncol. 1996;61:177-184.
26. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155-168.
27. Rhodes A, Jasani B, Balaton AJ, et al. Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe: documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays. Am J Clin Pathol. 2001;115:44-58.
28. Regitnig P, Reiner A, Dinges HP, et al. Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories. Virchows Arch. 2002;441:328-334.
29. Jalava P, Kuopio T, Huovinen R, et al. Immunohistochemical staining of estrogen and progesterone receptors: aspects for evaluating positivity and defining the cutpoints. Anticancer Res. 2005;25:2535-2542.
30. Kaplan PA, Frazier SR, Loy TS, et al. 1D5 and 6F11: an immunohistochemical comparison of two monoclonal antibodies for the evaluation of estrogen receptor status in primary breast carcinoma. Am J Clin Pathol. 2005;123:276-280.
31. Layfield LJ, Gupta D, Mooney EE. Assessment of tissue estrogen and progesterone receptor levels: a survey of current practice, techniques, and quantitation methods. Breast J. 2000;6:189-196.
32. Alberts SR, Ingle JN, Roche PR, et al. Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials. Cancer. 1996;78:764-772.
33. Clahsen PC, van de Velde CJ, Duval C, et al. The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer. Eur J Surg Oncol. 1999;25:356-363.
34. Elledge RM, Green S, Pugh R, et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer. 2000;89:111-117.
35. Love RR, Due NB, Alfred DC, et al. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol. 2002;20:2559-2566.
36. Taylor CR, Shi SR, Chaiwun B, et al. Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections: androgen receptor, estrogen receptor, progesterone receptor, p53 protein, proliferating cell nuclear antigen, and Ki-67 antigen revealed by antigen retrieval techniques. Hum Pathol. 1994;25:263-270.
37. Fleiss JL. Measuring nominal scale agreement among many raters. Psychol Bull. 1971;76:378-382.
38. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174.
39. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451-1467.
40. Marcot I, Migeon C, Parache RM, et al. A comparative study of hormone receptors in breast cancer with quantitative immunocytochemistry and biochemistry. Bull Cancer. 1997;84:613-618.
41. Moriki T, Takahashi T, Ueta S, et al. Hormone receptor status and HER2/neu overexpression determined by automated immunostainer on routinely fixed cytologic specimens from breast carcinoma: correlation with histologic sections determinations and diagnostic pitfalls. Diagn Cytopathol. 2004;30:251-256.
42. Sompuram SR, Kodela V, Ramanathan H, et al. Synthetic peptides identified from phage-displayed combinatorial libraries as immunodiagnostic assay surrogate quality-control targets. Clin Chem. 2002;48:410-420.
43. Rhodes A, Jasani B, Balaton AJ, et al. Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries. J Clin Pathol. 2000;53:292-301.
44. Riera J, Simpson JF, Tamayo R, et al. Use of cultured cells as a control for quantitative immunocytochemical analysis of estrogen receptor in breast cancer: the Quicgel method. Am J Clin Pathol. 1999;111:329-335.
45. Sompuram SR, Kodela V, Zhang K, et al. A novel quality control slide for quantitative immunohistochemistry testing. J Histochem Cytochem. 2002;50:1425-1434.